Who are High dose erythropoietin's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Aranesp, Epogen, Epogen, ARM B: IV iron + epoietin zeta sequence, rHuEPO, epoetin beta [NeoRecormon].

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/high-dose-erythropoietin.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-17 · How we verify

High dose erythropoietin — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

High dose erythropoietin (High dose erythropoietin) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Erythropoiesis-stimulating agent. Area: Hematology.

marketed Erythropoiesis-stimulating agent Erythropoietin receptor (EPOR) Hematology Small molecule Live · refreshed every 30 min

Target snapshot

High dose erythropoietin (High dose erythropoietin) — VA Office of Research and Development. High-dose erythropoietin stimulates erythroid progenitor cells in bone marrow to increase red blood cell production and hemoglobin levels.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
High dose erythropoietin TARGET	High dose erythropoietin	VA Office of Research and Development	marketed	Erythropoiesis-stimulating agent	Erythropoietin receptor (EPOR)
Aranesp	DARBEPOETIN ALFA	Amgen	marketed	Erythropoiesis-stimulating Agent [EPC]	Erythropoietin receptor	2001-01-01
Epogen	EPOETIN ALFA	Amgen	marketed	Erythropoiesis-stimulating Agent	Erythropoietin receptor	1989-01-01
Epogen	Epoetin Alfa-Epbx	Amgen	marketed	Erythropoiesis-stimulating agent (ESA)	Erythropoietin receptor	1989-01-01
ARM B: IV iron + epoietin zeta sequence	ARM B: IV iron + epoietin zeta sequence	Centre Francois Baclesse	marketed	Iron supplement + Erythropoiesis-stimulating agent (ESA)	Erythropoietin receptor (EPOR); iron as cofactor for hemoglobin synthesis
rHuEPO	rHuEPO	Amgen	marketed	Erythropoiesis-stimulating agent (ESA)	Erythropoietin receptor (EPOR)
epoetin beta [NeoRecormon]	epoetin beta [NeoRecormon]	Hoffmann-La Roche	marketed	Erythropoiesis-stimulating agent (ESA)	Erythropoietin receptor (EPOR)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Erythropoiesis-stimulating agent class)

VA Office of Research and Development · 2 drugs in this class
Hoffmann-La Roche · 1 drug in this class
Hospira, now a wholly owned subsidiary of Pfizer · 1 drug in this class
Jiangsu Hansoh Pharmaceutical Co., Ltd. · 1 drug in this class
Remedor Biomed Ltd · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). High dose erythropoietin — Competitive Intelligence Brief. https://druglandscape.com/ci/high-dose-erythropoietin. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab